Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 67%
Sell 8%
Strong Sell 0%

Bulls say

Amgen has demonstrated significant sales growth, with a remarkable 40% increase in total sales in the third quarter of 2025 compared to the same period in 2024, and notable performance from key products such as Repatha and Tezspire. The company's strategic investments in R&D, projected to grow over 20% in 2025 compared to 2024, highlight its commitment to innovation and bolstering its product pipeline. Additionally, the upward revision of FY25 revenue guidance to a range of $35.8-$36.6 billion further underscores Amgen's robust performance across its established franchises and signals continued momentum in the biotechnology sector.

Bears say

The financial outlook for Amgen appears negative, primarily due to projected revenue growth of only approximately 1% in 2026, which is further complicated by anticipated worldwide sales declines of about 28% and 39% for two of its flagship products, Prolia and Xgeva, respectively. Additionally, the company's research and development expenditures are expected to increase at a slower pace compared to prior years, indicating potential challenges in sustaining innovation and growth. While Amgen's emerging products and pipeline therapies show promise, there remains considerable uncertainty regarding their effectiveness in compensating for the anticipated decline in revenue following the loss of exclusivity for major product franchises.

Amgen (AMGN) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 67% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 12 analysts, Amgen (AMGN) has a Hold consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $316.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $316.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.